Innovative Hemostatic Technology BC3 Technologies has developed a proprietary chitosan-based aerosol product with high maximum hemostatic activity, stability, and versatility for wound management, making it highly competitive in both medical and consumer markets.

Rapid Market Adoption The professional version of BC3’s SEAL product has been quickly adopted by numerous police departments and EMS agencies across the United States, indicating strong demand in emergency response and first aid sectors.

Strategic Partnerships Partnering with First Aid Only to distribute its SEAL product significantly expands BC3T’s reach within first responder and consumer markets, presenting opportunities for increased sales channels and market penetration.

Growing Market Presence Recent product launches and partnerships position BC3 Technologies as a rising player in the first aid and trauma response innovation space, which could attract interest from government and defense sectors.

Funding and Revenue Opportunities With current revenue estimates between 1 million and 10 million dollars and recent modest funding of 150K, there is potential for investment to accelerate growth, product development, and expand sales efforts into larger institutional markets.